Incorporating biomarkers such as CSPG4 into the diagnostic and therapeutic landscape allows for a more refined and personalized approach to chordoma treatment, where interventions are tailored based on the specific genetic makeup of individual tumors [51]. This evidence concerns the gene CSPG4 and chordoma.